Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574676 | 0.86 | ALDH1A1 (0.57) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL21768192 | 0.84 | ALDH1A1 (0.62) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL23586971 | 0.84 | ALDH1A1 (0.61) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL6981751 | 0.81 | ALDH1A1 (0.60) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12846094 | 0.81 | GAA (0.61) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL6982172 | 0.81 | ALDH1A1 (0.60) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL22481582 | 0.79 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL14902197 | 0.79 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL20240120 | 0.79 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL485162 | 0.78 | SMN1; SMN2 (0.62) | ALDH1A1RAB9ANPC1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653018-A1 | ANTIBODY DRUG CONJUGATE AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024153149-A1 | ANTIBODY DRUG CONJUGATE AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
| EP-4137159-A1 | ANTIBODY DRUG CONJUGATES | Sorrento Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3250238-B1 | ANTIBODY DRUG CONJUGATES | SORRENTO THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | SORRENTO THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10836821-B2 | Drug-conjugates with a targeting molecule and two different drugs | SORRENTO THERAPEUTICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10590165-B2 | Antibody drug conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3520817-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | Concortis Biosystems, Corp (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190091345-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | HANGZHOU ADCORIS BIOPHARMA CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| US-9981046-B2 | Drug-conjugates, conjugation methods, and uses thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170190736-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190736-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016123412-A1 | ANTIBODY DRUG CONJUGATES | SORRENTO THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590165-B2 | Antibody drug conjugates | STT3B, STT3A, HSD17B14 | ALDH1A1 1383/4885RAB9A 1096/4885NPC1 46/4885 |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | ALDH1A1 154/4885RAB9A 764/4885NPC1 330/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | ALDH1A1 154/4885RAB9A 764/4885NPC1 330/4885 |
| US-20170190736-A1 | Antibody Drug Conjugates | STT3B, STT3A, HSD17B14 | ALDH1A1 1383/4885RAB9A 1096/4885NPC1 46/4885 |
| US-20190091345-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | ERBB2, EGFR, ERBB3 | ALDH1A1 2915/4885RAB9A 2134/4885NPC1 1837/4885 |
| US-20210017274-A1 | Drug-Conjugates With a Targeting Molecule and Two Different Drugs | ERBB2, ABCG2, DYNLL2 | ALDH1A1 1088/4885RAB9A 627/4885NPC1 2589/4885 |
| US-10836821-B2 | Drug-conjugates with a targeting molecule and two different drugs | ERBB2, ABCG2, DYNLL2 | ALDH1A1 1088/4885RAB9A 627/4885NPC1 2589/4885 |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | ERBB2, ABCG2, DYNLL2 | ALDH1A1 1088/4885RAB9A 627/4885NPC1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.